Comparison of efficacy and safety of 1- and 3-month luteinizing hormone-releasing hormone agonist depots as initial therapies for prostate cancer

Ishizuka, Osamu; Nishizawa, Osamu; Nishizawa, Shuji; Satoh, Tomoya; Wajiki, Masahisa; Kiyokawa, Hideo; Inoué, Yoshihiro; Kobayashi, Shinya; Mizusawa, Hiroya; Nakagawa, Tatsuo

doi:10.1007/s10147-012-0413-9

Cited by 2 publications

(6 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, a Japanese trial demonstrated that among hormone treatment-naïve patients with prostate cancer, goserelin 10.8-mg depot treatment decreased the mean serum testosterone from 507 ng/dL at baseline to 10 ng/dL at week 24, which was slightly lower than the level reported in this study (29.2 ng/dL). The mean serum PSA decreased from 52.4 ng/mL at baseline to 0.9 ng/mL at week 24, which was higher than the level reported in this study (0.5 ng/mL) 19 . Factors that contributed to these differences are complex.…”

Section: Discussioncontrasting

confidence: 89%

“…The high incidence (7.1%) of urinary tract infections could be attributed to the high proportion [38.1% (112/294)] of patients who underwent an RP, after which a urinary tract infection is a common complication 29 , 30 . The 6.5% incidence of anemia was not unexpected because hemoglobin decreased was reported in > 25% of patients receiving goserelin treatment in the aforementioned Japanese trial 19 . However, hot flush, reported to be the most common TEAE in previous trials (incidence, 51%–70%) 17 , 18 , 20 , 23 , was uncommon (2.0%) in this study, possibly because patients were less likely to disclose mild AEs in real-world settings and not questioned specifically for the symptom as in clinical trials.…”

Section: Discussionmentioning

confidence: 85%

“…Notably, the baseline patient characteristics differed substantially between the two studies. Specifically, patients included in the Japanese trial were older (mean age at baseline, 75.0 vs. 70.2 years) and had a higher proportion with clinical stage T1–2 (64.8% vs. 36.7%) 19 . Moreover, the Japanese trial included patients with metastatic disease (clinical stage M1, 24.1%) 19 ; patients with metastatic disease were excluded from the current study.…”

Section: Discussionmentioning

confidence: 99%

“…Specifically, patients included in the Japanese trial were older (mean age at baseline, 75.0 vs. 70.2 years) and had a higher proportion with clinical stage T1–2 (64.8% vs. 36.7%) 19 . Moreover, the Japanese trial included patients with metastatic disease (clinical stage M1, 24.1%) 19 ; patients with metastatic disease were excluded from the current study. The influence of these factors on testosterone and PSA levels during ADT requires further research.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancer

Chen,

Wang,

Chen

et al. 2024

Cancer Biol Med

View full text Add to dashboard Cite

Objective: Real-word data on long-acting luteinizing hormone-releasing hormone (LHRH) agonists in Chinese patients with prostate cancer are limited. This study aimed to determine the real-world effectiveness and safety of the LHRH agonist, goserelin, particularly the long-acting 10.8-mg depot formulation, and the follow-up patterns among Chinese prostate cancer patients. Methods: This was a multicenter, prospective, observational study in hormone treatment-naïve patients with localized or locally advanced prostate cancer who were prescribed goserelin 10.8-mg depot every 12 weeks or 3.6-mg depot every 4 weeks with or without an anti-androgen. The patients had follow-up evaluations for 26 weeks. The primary outcome was the effectiveness of goserelin in reducing serum testosterone and prostate-specific antigen (PSA) levels. The secondary outcomes included testosterone and PSA levels, attainment of chemical castration (serum testosterone <50 ng/dL), and goserelin safety. The exploratory outcome was the monitoring pattern for serum testosterone and PSA. All analyses were descriptive. Results: Between September 2017 and December 2019, a total of 294 eligible patients received ≥ 1 dose of goserelin; 287 patients (97.6%) were treated with goserelin 10.8-mg depot. At week 24 ± 2, the changes from baseline [standard deviation (95% confidence interval)] in serum testosterone (n = 99) and PSA (n = 131) were −401.0 ng/dL [308.4 ng/dL (−462.5, −339.5 ng/dL)] and −35.4 ng/mL [104.4 ng/mL (−53.5, −17.4 ng/mL)], respectively. Of 112 evaluable patients, 100 (90.2%) achieved a serum testosterone level < 50 ng/dL. Treatment-emergent adverse events (TEAEs) and severe TEAEs occurred in 37.1% and 10.2% of patients, respectively. The mean testing frequency (standard deviation) was 1.6 (1.5) for testosterone and 2.2 (1.6) for PSA. Conclusions: Goserelin 10.8-mg depot effectively achieved and maintained castration and was well-tolerated in Chinese patients with localized and locally advanced prostate cancer.

show abstract

Section: Discussioncontrasting

confidence: 89%

Section: Discussionmentioning

confidence: 85%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancer

Chen,

Wang,

Chen

et al. 2024

Cancer Biol Med

View full text Add to dashboard Cite

show abstract

“…Six studies compared the monthly 3.6 mg and the 10.8 mg dose given every three months of goserelin in patients with advanced prostate cancer. The effects on testosterone levels were similar in the studies [45][46][47][48][49][50].…”

Section: Advanced Prostate Cancersupporting

confidence: 79%

GnRH agonists and antagonists in prostate cancer

Janknegt¹,

Boone²,

Erdkamp³

et al. 2014

GaBI J

View full text Add to dashboard Cite

This manuscript describes the System of Objectifi ed Judgement Analysis (SOJA) method applied to gonadotropin-releasing hormone (GnRH) agonists and antagonists in prostate cancer. The following selection criteria were used: effi cacy, safety, tolerability, dosage frequency, user-friendly formulation, drug interactions, precaution and documentation. The GnRH agonists goserelin and leuprorelin show the highest scores, mainly based on more extensive documentation compared with the agonists buserelin and triptorelin. The antagonists abarelix and degarelix show low scores, based on a higher incidence of adverse events, a higher dosage frequency, more drug interactions and a more limited documentation compared with the agonists. The availability of a generic formulation of leuprorelin may lead to a reduction in cost.

show abstract

Comparison of efficacy and safety of 1- and 3-month luteinizing hormone-releasing hormone agonist depots as initial therapies for prostate cancer

Abstract: Background: We compared the efficacy and safety in prostate cancer patients of 1-and

Cited by 2 publications

References 8 publications

Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancer

Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancer

GnRH agonists and antagonists in prostate cancer

Contact Info

Product

Resources

About